Sun Yat-sen University Cancer Center Reports Findings in Prescription Opioids (Trends in pain undertreatment among lung cancer patients at the EOL: Analysis of urban city medical insurance data in China): Opioids – Prescription Opioids

Insurance Daily News

2024 FEB 19 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Opioids - Prescription Opioids is the subject of a report. According to news reporting originating in Guangzhou, People’s Republic of China, by NewsRx journalists, research stated, “Cancer-related pain is one of the common priority symptoms in advanced lung cancer patients at the end-of-life (EOL). Alleviating pain is undoubtedly a critical component of palliative care in lung cancer.”

Financial support for this research came from National Natural Science Foundation of China.

The news reporters obtained a quote from the research from Sun Yat-sen University Cancer Center, “Our study was initiated to examined trends in opioid prescription-level outcomes as potential indicators of undertreated pain in China. This study used data on 1330 patients diagnosed with lung cancer of urban city medical insurance in China who died between 2014 and 2017. Opioid prescription-level outcomes were determined by annual trends of the proportion of patients filling an opioid prescription, the total dose of opioids filled by decedents, and morphine milligram equivalents per day (MMED) at the EOL (defined as the 60 days before death). We further analyzed monthly changes in the number of opioid prescriptions filled, MMED, and mean daily dose of opioids per prescription (MDDP) of the last 60 days of life by year at death and age, respectively. A total of 959 patients with exact dates of death were included, with 432 cases (45.06%; 95% CI: 44.36%-45.77%) receiving at least one opioid prescription at the EOL. The declining trends were shown in the proportion of patients filling any opioid prescription, the total dose of opioids filled by decedents and MMED, with an annual decrease of 0.341% (p = 0.01), 104.23 mg (p = 0.011) and 2.84 mg (p = 0.014), respectively. Within the 31-60 days to the 0-30 days of life, the MMED declined 6.08 mg (95% CI: -7.14 to -5.03; p = 0.000351), while the number of opioid prescriptions rose 0.66 (95% CI: 0.160-1.16; p = 0.025). Like the MMED, the MDDP fell 4.11 mg (95% CI: -5.86 to -2.37; p = 0.005) within the last month before death compared to the previous month. Terminal lung cancer populations in urban China have experienced reduced access to opioids at the EOL. The clinicians did not prescribe a satisfactory dose of opioids per prescription, while the patients suffered increasing pain in the last 30 days of life.”

According to the news reporters, the research concluded: “Sufficient opioid analgesic administration should be advocated for lung cancer patients during the EOL period.”

For more information on this research see: Trends in pain undertreatment among lung cancer patients at the EOL: Analysis of urban city medical insurance data in China. Thoracic Cancer, 2024. Thoracic Cancer can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - http://www.wiley.com/; Thoracic Cancer - http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1759-7714)

Our news correspondents report that additional information may be obtained by contacting Yihua Huang, Dept. of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China. Additional authors for this research include Jiani Zheng, Junyi He, Huangqiang Zhou, Tingting Liu, Jie Huang, Mengting Shi, Yuanyuan Zhao, Wenfeng Fang, Yunpeng Yang and Li Zhang.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1111/1759-7714.15240. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.